Identification and validation of novel drug targets in Mycobacterium tuberculosis

Drug Discovery Today

Volumn 22, Issue 3, 2017, Pages 503-509

  Singh, Vinayak ^a   Mizrahi, Valerie ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BACTERIAL PROTEIN; CARBOXYQUINOXALINE DERIVATIVE; CYTIDINE TRIPHOSPHATE SYNTHASE; DECAPRENYL PHOSPHO DEXTRO ARABINOFURANOSE; ETHA PROTEIN; ETHIONAMIDE; FLUOROURACIL; GLYCOSIDASE; INHA PROTEIN; ISONIAZID; LANSOPRAZOLE; MANNOSYLTRANSFERASE; NATURAL PRODUCT; OXIDOREDUCTASE; PIMA PROTEIN; PIPERIDINE DERIVATIVE; PYRAZINAMIDE; PYRIDOMYCIN; PYRIMIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; RV2466C; SPIROPIPERIDINE DERIVATIVE; STREPTOMYCIN; THIENOPYRIMIDINE; THIOPHENE DERIVATIVE; THIOPHENECARBOXAMIDE DERIVATIVE; TRICLOSAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL CELL WALL; BIOSYNTHESIS; DRUG DESIGN; DRUG IDENTIFICATION; DRUG TARGETING; HUMAN; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; POLYPHARMACOLOGY; PYRIMIDINE METABOLISM; REVIEW; VALIDATION PROCESS; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84995785346     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.09.010     Document Type: Review

References (71)

1. 1 Daniel, T.M., The history of tuberculosis. Respir. Med. 100 (2006), 1862–1870.
2. 2 WHO, Global Tuberculosis Report 2015., 2015, WHO.
3. 3 Griffin, J.E., et al. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog., 7, 2011, e1002251.
4. 4 Rengarajan, J., et al. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 8327–8332.
5. 5 Sassetti, C.M., et al. Comprehensive identification of conditionally essential genes in mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 12712–12717.
6. 6 Sassetti, C.M., et al. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48 (2003), 77–84.
7. 7 Payne, D.J., et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6 (2007), 29–40.
8. 8 Andries, K., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 (2005), 223–227.
9. 9 Matsumoto, M., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 3, 2006, e466.
10. 10 Lechartier, B., et al. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol. Med. 6 (2014), 158–168.
11. 11 Dutta, N.K., et al. Genetic requirements for the survival of tubercle bacilli in primates. J. Infect. Dis. 201 (2010), 1743–1752.
12. 12 Lamichhane, G., et al. Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect. Immun. 73 (2005), 2533–2540.
13. 13 Balganesh, T., Furr, B., Molecular approaches to target discovery: evaluating targets for antituberculosis drug discovery programmes. Infect. Disord. Drug Targets 7 (2007), 120–126.
14. 14 Evans, J.C., Mizrahi, V., The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis. Front. Microbiol., 6, 2015, 812.
15. 15 Schnappinger, D., Ehrt, S., Regulated expression systems for Mycobacteria and their applications. Microbiol. Spectr., 2(1), 2014, 10.1128/microbiolspec.MGM2-0018-2013 MGM2-0018-2013.
16. 16 Schnappinger, D., et al. Construction of conditional knockdown mutants in mycobacteria. Methods Mol. Biol. 1285 (2015), 151–175.
17. 17 Singh, A.K., et al. Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system. Nucleic Acids Res., 2016 Published online July 12, 2016. http://dx.doi.org/10.1093/nar/gkw625.
18. 18 Carroll, P., et al. Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl. Environ. Microbiol. 77 (2011), 5040–5043.
19. 19 Boldrin, F., et al. The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo. J. Bacteriol. 196 (2014), 3441–3451.
20. 20 Kolly, G.S., et al. Assessing the essentiality of the decaprenyl-phospho-d-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. Mol. Microbiol. 92 (2014), 194–211.
21. 21 Djaout, K., et al. Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis. Sci. Rep., 6, 2016, 27792.
22. 22 Singh, V., et al. The complex mechanism of antimycobacterial action of 5-fluorouracil. Chem. Biol. 22 (2015), 63–75.
23. 23 Abrahams, K.A., et al. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One, 7, 2012, e52951.
24. 24 Park, S.W., et al. Target-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis. Chem. Biol. 22 (2015), 76–86.
25. 25 Makarov, V., et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324 (2009), 801–804.
26. 26 Boldrin, F., et al. Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Res., 38, 2010, e134.
27. 27 Dhar, N., et al. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable beta-lactam antibiotic. Antimicrob. Agents Chemother. 59 (2015), 1308–1319.
28. 28 Brecik, M., et al. DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization. ACS Chem. Biol. 10 (2015), 1631–1636.
29. 29 Lucarelli, A.P., et al. Mycobacterium tuberculosis phosphoribosylpyrophosphate synthetase: biochemical features of a crucial enzyme for mycobacterial cell wall biosynthesis. PLoS One, 5, 2010, e15494.
30. 30 Kordulakova, J., et al. Definition of the first mannosylation step in phosphatidylinositol mannoside synthesis. PimA is essential for growth of mycobacteria. J. Biol. Chem. 277 (2002), 31335–31344.
31. 31 Sipos, A., et al. Lead selection and characterization of antitubercular compounds using the Nested Chemical Library. Tuberculosis 95:Suppl. 1 (2015), S200–S206.
32. 32 Abrahams, G.L., et al. Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem. Biol. 19 (2012), 844–854.
33. 33 Sala, C., Hartkoorn, R.C., Tuberculosis drugs: new candidates and how to find more. Fut. Microbiol. 6 (2011), 617–633.
34. 34 Cho, S.H., et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51 (2007), 1380–1385.
35. 35 Grant, S.S., et al. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem. Biol. 8 (2013), 2224–2234.
36. 36 Gold, B., et al. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis. Methods Mol. Biol. 1285 (2015), 293–315.
37. 37 Honore, N., et al. Novel mutation in 16S rRNA associated with streptomycin dependence in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39 (1995), 769–770.
38. 38 Sala, C., et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54 (2010), 4150–4158.
39. 39 Zhang, M., et al. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56 (2012), 5782–5789.
40. 40 Christophe, T., et al. High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog., 5, 2009, e1000645.
41. 41 VanderVen, B.C., et al. Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment. PLoS Pathog., 11, 2015, e1004679.
42. 42 Pethe, K., et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19 (2013), 1157–1160.
43. 43 Moraski, G.C., et al. Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity. ACS Med. Chem. Lett. 2 (2011), 466–470.
44. 44 Tang, J., et al. Design, synthesis, and biological evaluation of pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents. ACS Med. Chem. Lett. 6 (2015), 814–818.
45. 45 Stanley, S.A., et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog., 10, 2014, e1003946.
46. 46 Rybniker, J., et al. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host Microbe 16 (2014), 538–548.
47. 47 Rybniker, J., et al. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat. Commun., 6, 2015, 7659.
48. 48 Ioerger, T.R., et al. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One, 8, 2013, e75245.
49. 49 Hartkoorn, R.C., et al. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58 (2014), 2979–2981.
50. 50 Maeda, K., et al. A new antibiotic, pyridomycin. J. Antibiot., 6, 1953, 140.
51. 51 Hartkoorn, R.C., et al. Towards a new tuberculosis drug: pyridomycin – nature's isoniazid. EMBO Mol. Med. 4 (2012), 1032–1042.
52. 52 Hartkoorn, R.C., et al. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat. Chem. Biol. 10 (2014), 96–98.
53. 53 Neres, J., et al. 2-Carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem. Biol. 10 (2015), 705–714.
54. 54 Grzegorzewicz, A.E., et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8 (2012), 334–341.
55. 55 Tahlan, K., et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56 (2012), 1797–1809.
56. 56 Onajole, O.K., et al. Preliminary structure–activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. J. Med. Chem. 56 (2013), 4093–4103.
57. 57 Rao, S.P., et al. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci. Transl. Med., 5, 2013, 214ra168.
58. 58 Stec, J., et al. Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection. J. Med. Chem. 59 (2016), 6232–6247.
59. 59 Remuinan, M.J., et al. Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One, 8, 2013, e60933.
60. 60 Lun, S., et al. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nat. Commun., 4, 2013, 2907.
61. 61 La Rosa, V., et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56 (2012), 324–331.
62. 62 Stanley, S.A., et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7 (2012), 1377–1384.
63. 63 Tantry, S.J., et al. Whole cell screen based identification of spiropiperidines with potent antitubercular properties. Bioorg. Med. Chem. Lett. 25 (2015), 3234–3245.
64. 64 Naik, M., et al. 4-Aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. J. Med. Chem. 57 (2014), 5419–5434.
65. 65 Naik, M., et al. 2-Phenylindole and arylsulphonamide: novel scaffolds bactericidal against Mycobacterium tuberculosis. ACS Med. Chem. Lett. 5 (2014), 1005–1009.
66. 66 Li, W., et al. Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3. Antimicrob. Agents Chemother. 60 (2016), 5198–5207.
67. 67 Li, W., et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58 (2014), 6413–6423.
68. 68 Mori, G., et al. Thiophenecarboxamide derivatives activated by EthA kill Mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG. Chem. Biol. 22 (2015), 917–927.
69. 69 Albesa-Jove, D., et al. Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 9 (2014), 1567–1575.
70. 70 Albesa-Jove, D., et al. The redox state regulates the conformation of Rv2466c to activate the antitubercular prodrug TP053. J. Biol. Chem. 290 (2015), 31077–31089.
71. 71 Kling, A., et al. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. Science 348 (2015), 1106–1112.